TEL AVIV, Israel, July 13, 2022 /PRNewswire/ — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS™) System to treat a variety of hypertensive disorders, announced that on May 30th 2022 the first patient was treated with its Renal Artery Denervation TIVUS™ technology, as part of the recently FDA IDE-approved Pilot […]
Coronary/Structural Heart
Intratech Medical enrolls patients to first ever human study for treatment of accute heart attacks using Booster™ – coronary sinus spiral balloon therapy
TEL AVIV, Israel, July 13, 2022 /PRNewswire/ — Intratech Medical, developer of the Booster™ spiral balloon therapy for the treatment of AMI patients, announced the successful enrollment of two patients in a multi-center first in human study to assess the safety and technical performance of their Booster balloon in the treatment of patients […]
Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab
Additional Pharmacodynamic Data on Abelacimab Released at the 2022 Congress of the International Society on Thrombosis and Haemostasis (ISTH) CAMBRIDGE, Mass., July 13, 2022 /PRNewswire/ — Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that four new research updates were presented on abelacimab during the […]
Filling gap in market: VenusP-Valve™ approved by China’s NMPA
HANGZHOU, China, July 13, 2022 /PRNewswire/ — On July 11, 2022, VenusP-ValveTM, Venus Medtech’s in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, was approved by China’s National Medical Products Administration (NMPA) for the treatment of severe pulmonary regurgitation (≥3+) in patients after congenital heart defects (CHD) procedure with native right ventricular outflow tract (RVOT). […]
NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales
— Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who […]
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
Novartis Pharmaceuticals Corporation to collaborate on development of new medical device software for earlier detection and intervention in cardiovascular disease CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of […]
Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch® Ventricular Restoration System
Designation Allows for Expedited Review of Transcatheter Therapy Designed to Improve Left Ventricular Structure and Function in Heart Failure Patients with Reduced Ejection Fraction SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. Food and Drug Administration […]
Successful Heart Xenotransplant Experiments at NYU Langone Set Protocol for Pig-to-Human Organ Transplantation
NEW YORK, July 12, 2022 /PRNewswire/ — A team at NYU Langone Health successfully transplanted two genetically engineered pig hearts into recently deceased humans in June and July, marking the latest advances toward addressing the nationwide organ shortage and developing a clinical protocol that would provide an alternative supply of organs for […]
Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid overloaded heart failure (HF) patients with Aquadex® ultrafiltration (UF) in the […]
scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure
Study results favor FUROSCIX® versus “treatment as usual” in composite primary endpoint and all secondary endpoints FUROSCIX demonstrated an acceptable tolerability profile Company on track for Q4 2022 commercial launch of FUROSCIX, if approved BURLINGTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on […]



